Inspira Technologies Signs Agreement With Glo-Med Networks To Potentially Provide $59M For Deployment Of 3,889 HYLA Blood Sensors

Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (NASDAQ: IINNW) (the "Company" or "Inspira Technologies"), a groundbreaking respiratory support technology company, following

Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (NASDAQ: IINNW) (the “Company” or “Inspira Technologies”), a groundbreaking respiratory support technology company, following yesterday’s announcement of the development of its new HYLA™ blood sensor, announced today that it has signed an exclusive summary distribution agreement with the U.S. based Glo-Med Networks (“Glo-Med”), for the distribution of the HYLA™ blood sensor device and disposable units across 6 states in the United States (Texas, New Jersey, New York, Florida, North Carlina and South Carolina).

HYLA™ blood sensor - designed to provide real-time continuous measurements of key blood parameters

The summary distribution agreement will be followed by a more comprehensive agreement. The agreement has an initial term of 3 years, subject to completion of product development and regulatory approvals. The parties will collaborate on the marketing and deployment of the HYLATM blood sensor. Without the need to take actual blood samples from patients, Inspira Technologies’ non-invasive optical blood sensor is being designed to perform real-time and continuous blood monitoring to alert physicians of immediate signs of changes in a patient’s clinical condition.

Pursuant to the agreement, and in order to maintain exclusivity in the territory, Glo-Med has committed to purchase a minimum order of 3,889 HYLATM blood sensors and 264,873 disposable units for deployment at hospitals and medical centers, subject to regulatory approvals for the sale and marketing of the HYLATM blood sensor device in the 6 states within the United States.

This is the second distribution agreement reached with Glo-Med for the U.S. market, in addition to the agreement signed in January 2022, for the distribution of the Company’s ART™ system.

The Company has additional distribution agreements internationally, targeting a total of $189 million in Israel and Europe (Spain, Portugal, Poland, Czech and Slovakia). All agreements for the ART™ system are over a 7-year period and are subject to the completion of product development and regulatory approvals.

The HYLA™ blood sensor and ART™ system have not been tested or used in humans and are subject to completion of development and regulatory approvals.

Related Posts
Read More

Psyched: LSD Microdosing For Depression, DMT For Anxiety, MDMA Octopuses And More

Microdosing LSD For Major Depression Treatment Seeks Further Clinical Validation Via New Study Australian psychedelics company MindBio Therapeutics Corp. was granted approval by both the Ethics committee and the Clinical Trials Registry to begin the world's first Phase 2a take-home LSD microdosing trial in patients with Major Depressive Disorder (MDD).